Any feedback?
Please rate this page
(all_enzymes.php)
(0/150)

BRENDA support

4.1.2.27: sphinganine-1-phosphate aldolase

This is an abbreviated version!
For detailed information about sphinganine-1-phosphate aldolase, go to the full flat file.

Word Map on EC 4.1.2.27

Reaction

sphinganine 1-phosphate
=
Phosphoethanolamine
 +
palmitaldehyde

Synonyms

aldolase, dihydrosphingosine 1-phosphate, Dihydrosphingosine 1-phosphate aldolase, dihydrosphingosine phosphate lyase, Dpl1, Dpl1p, LegS2, S-1-P-lyase, S1P lyase, S1P-lyase, S1PL, S1PL2021, Sgpl1, sphinganine 1-phosphate lyase, sphinganine-1-phosphate aldolase, sphinganine-1-phosphate lyase, sphinganine-1-phosphate-alkanal-lyase, sphingosine 1-phosphate lyase, sphingosine phosphate lyase, sphingosine-1-phosphate lyase, sphingosine-phosphate lyase, SPL, SPL1

ECTree

     4 Lyases
         4.1 Carbon-carbon lyases
             4.1.2 Aldehyde-lyases
                4.1.2.27 sphinganine-1-phosphate aldolase

Inhibitors

Inhibitors on EC 4.1.2.27 - sphinganine-1-phosphate aldolase

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(1R,2S,3R)-1-(1H,1'H-2,2'-biimidazol-4-yl)butane-1,2,3,4-tetraol
-
inhibitory to sphinganine 1-phosphate lyase. 53% decrease in circulating lymphocytes after 30 mg/kg oral dose
(1R,2S,3R)-1-(2-(1-benzyl-1H-1,2,4-triazol-3-yl)-1H-imidazol-4-yl)butane-1,2,3,4-tetraol
-
inhibitory to sphinganine 1-phosphate lyase. 41% decrease in circulating lymphocytes after 30 mg/kg oral dose
(1R,2S,3R)-1-(2-(thiazol-4-yl)-1H-imidazol-4-yl)butane-1,2,3,4-tetraol
-
inhibitory to sphinganine 1-phosphate lyase. 33% decrease in circulating lymphocytes after 30 mg/kg oral dose
(2R,3R)-2-azido-3-hydroxyoctadecyl phosphate
(2R,3R,4E)-2-azido-3-hydroxyoctadec-4-en-1-yl phosphate
(2R,3S)-2-azido-3-hydroxyoctadecyl phosphate
(2R,3S,4E)-2-azido-3-hydroxyoctadec-4-en-1-yl phosphate
(2S,3R)-2-azido-3-hydroxyoctadecyl phosphate
(2S,3R,4E)-2-azido-3-hydroxyoctadec-4-en-1-yl phosphate
(2S,3S)-2-azido-3-hydroxyoctadecyl phosphate
(2S,3S,4E)-2-azido-3-hydroxyoctadec-4-en-1-yl phosphate
(R)-1-benzyl-4-(3-methyl-4-(5-(trifluoromethyl)pyridin-2-yl)-piperazin-1-yl)phthalazine
-
-
(R)-1-benzyl-4-(3-methyl-4-(5-nitropyridin-2-yl)piperazin-1-yl)-phthalazine
-
-
(R)-1-benzyl-4-(4-(5-cyanopyridin-2-yl)-3-methylpiperazin-1-yl)phthalazine-6-carbonitrile
-
-
(R)-4-benzyl-1-(4-(5-cyanopyridin-2-yl)-3-methylpiperazin-1-yl)phthalazine-6-carbonitrile
-
-
(R)-6-(2-methyl-4-(4-phenethylphthalazin-1-yl)piperazin-1-yl)nicotinonitrile
-
-
(R)-6-(2-methyl-4-(4-phenylphthalazin-1-yl)piperazin-1-yl)-nicotinonitrile
-
-
(R)-6-(4-(4-benzyl-6-(trifluoromethyl)phthalazin-1-yl)-2-methylpiperazin-1-yl)nicotinonitrile
-
-
(R)-6-(4-(4-benzyl-6-chlorophthalazin-1-yl)-2-methylpiperazin-1-yl)nicotinonitrile
-
-
(R)-6-(4-(4-benzyl-7-(trifluoromethyl)phthalazin-1-yl)-2-methylpiperazin-1-yl)nicotinonitrile
-
-
(R)-6-(4-(4-benzyl-7-chlorophthalazin-1-yl)-2-methylpiperazin-1-yl)nicotinonitrile
-
-
(R)-6-(4-(4-benzylphthalazin-1-yl)-2-ethylpiperazin-1-yl)nicotinonitrile
-
-
(R)-6-(4-(4-benzylphthalazin-1-yl)-2-isopropylpiperazin-1-yl)-nicotinonitrile
-
-
(R)-6-(4-(4-benzylphthalazin-1-yl)-2-methylpiperazin-1-yl)-nicotinic acid
-
-
(R)-6-(4-(4-chlorophthalazin-1-yl)-2-methylpiperazin-1-yl)-nicotinonitrile
-
-
(S)-6-(4-(4-benzylphthalazin-1-yl)-2-(hydroxymethyl)piperazin-1-yl)nicotinonitrile
-
-
1-(4-((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-1H-imidazol-2-yl)ethanone
-
inhibitory to sphinganine 1-phosphate lyase. 25% decrease in circulating lymphocytes after 30 mg/kg oral dose
1-benzyl-4-[(3R)-4-(5-cyanopyridin-2-yl)-3-methylpiperazin-1-yl]phthalazine-6-carbonitrile
-
-
1-deoxydihydrosphingosine 1-phosphonate
1-deoxysphinganine 1-phosphonate
1-desoxysphinganine 1-phosphonate
1-{5-[(1R,2S,3R)-1,2,3,4-tetrahydroxybutyl]-1H-imidazol-2-yl}ethanone
-
when given overnight at 25 mg/l in drinking water, tetrahydroxybutylimidazole raises sphingosine 1-phosphate levels and reduces SPL activity
2-acetyl-4(5)-tetrahydroxybutyl imidazole
-
inhibitory. Following the oral administration of 10 and 100 mg/kg 2-acetyl-4(5)-tetrahydroxybutyl imidazole to male rats, 2-acetyl-4(5)-tetrahydroxybutyl imidazole is rapidly absorbed and reaches a plasma peak level at 1 h post-dosing. Splenic S1P increases and reaches the peak level at 24 h. Blood lymphocyte count decreases as the splenic S1P level increases. 2-Acetyl-4(5)-tetrahydroxybutyl imidazole plasma concentration is linked to splenic S1P concentration using an indirect model incorporated with a four-step signal transduction model. In turn, the S1P level is directly coupled with blood lymphocyte number
2-acetyl-4-(1R,2S,3R,4-tetrahydroxybutyl)-1H-imidazole
-
-
2-acetyl-4-(1R,2S,3R,4-tetrahydroxybutyl)-imidazole
2-acetyl-4-(tetrahydroxybutyl)imidazole
-
the enzyme is inhibited indirectly by 2-acetyl-4-(tetrahydroxybutyl)imidazole under conditions of vitamin B6 deficiency
2-acetyl-4-tetrahydroxybutyl-imidazole
2-acetyl-4-tetrahydroxybutylimidazole
2-vinyl dihydrosphingosine
2-vinyl sphinganine phosphate
-
50% inhibition at 0.0024 mM
2-vinyldihydro-sphingosine 1-phosphate
2-vinyldihydrosphingosine 1-phosphate
2-vinylsphinganine 1-phosphate
-
-
2D,3L-sphinganine-phosphate
-
competitive
4'-deoxypyridoxine
4-amino-N-[4-(1H-imidazol-1-yl)benzyl]-5-oxo-2-(piperidin-1-yl)-8-(tetrahydrofuran-2-ylmethyl)-5,8-dihydropyrido[2,3-d]pyrimidine-6-carboxamide
-
-
4-chloromercuribenzoate
-
alkylates a cysteine residue
4-deoxypyridoxine
5-cyclopropyl-N-[2-[(4-ethoxy-2,5-dimethylbenzyl)amino]-1-(4-fluorophenyl)ethyl]-1,2-oxazole-3-carboxamide
-
-
5-cyclopropyl-N-[2-[(4-methoxy-2,5-dimethylbenzyl)amino]-1-phenylethyl]-1,2-oxazole-3-carboxamide
-
-
5-methoxy-N-[2-[(4-methoxy-2,5-dimethylbenzyl)amino]-1-phenylethyl]-1,2-oxazole-3-carboxamide
-
-
6-[(2R)-4-(4-benzyl-7-chlorophthalazin-1-yl)-2-methylpiperazin-1-yl]pyridine-3-carbonitrile
-
-
6-[(2R)-4-(4-benzylphthalazin-1-yl)-2-methylpiperazin-1-yl]pyridine-3-carbonitrile
6-[4-(4-benzylphthalazin-1-yl)piperazin-1-yl]pyridine-3-carbonitrile
-
benzylphthalazine
-
-
bisulfite
carboplatin
-
cells overexpressing enzyme show increased sensitivity
chymotrypsin
-
-
-
cisplatin
-
cells overexpressing enzyme show increased sensitivity, mediated by death kinase p38
cyanide
cysteine
deoxypyridoxin phosphate
-
inhibits
deoxypyridoxine
Deoxypyridoxine phosphate
deoxysphinganine 1-phosphonate
-
competitive
doxorubicin
-
cells overexpressing enzyme show increased sensitivity
ethyl 6-[(2R)-4-(4-benzylphthalazin-1-yl)-2-methylpiperazin-1-yl]pyridine-3-carboxylate
-
FTY720
FTY720 phosphate
-
less potent inhibitor than FTY720, effects only at 0.03 mM
fumonisin B1
-
10 mg/kg inhibits the expression of sphingosine 1-phosphate lyase
iodoacetamide
LX2931
N,N-dimethyldodecylamine N-oxide
-
50% inhibition at 0.05 mM
N-(2-[[2,5-dimethyl-4-(2,2,2-trifluoroethoxy)benzyl]amino]-1-phenylethyl)-5-methyl-1,2-oxazole-3-carboxamide
-
-
N-(2-[[2,5-dimethyl-4-(pyridin-4-ylmethoxy)benzyl]amino]-1-phenylethyl)-5-methyl-1,2-oxazole-3-carboxamide
-
-
N-(2-[[4-methoxy-2-methyl-5-(trifluoromethyl)benzyl]amino]-1-phenylethyl)-5-methyl-1,2-oxazole-3-carboxamide
-
-
N-ethylmaleimide
N-[(1R,2S)-2-hydroxy-1-hydroxymethyl-2-(2-tridecyl-1-cyclopentenyl)ethyl]octanamide
N-[1-(4-fluorophenyl)-2-[(4-methoxy-2,5-dimethylbenzyl)amino]ethyl]-5-methyl-1,2-oxazole-3-carboxamide
-
-
N-[1-[3-(4-amino-4-oxobutyl)phenyl]-2-[(4-methoxy-2,5-dimethylbenzyl)amino]ethyl]-5-methyl-1,2-oxazole-3-carboxamide
-
-
N-[1-[4-(3-hydroxyprop-1-yn-1-yl)phenyl]-2-[(4-methoxy-2,5-dimethylbenzyl)amino]ethyl]-5-methyl-1,2-oxazole-3-carboxamide
-
-
N-[1-[4-(4-amino-4-oxobutyl)phenyl]-2-[(4-methoxy-2,5-dimethylbenzyl)amino]ethyl]-5-methyl-1,2-oxazole-3-carboxamide
-
-
N-[2-[(4-butoxy-2,5-dimethylbenzyl)amino]-1-phenylethyl]-5-methyl-1,2-oxazole-3-carboxamide
-
-
N-[2-[(4-ethoxy-2,5-dimethylbenzyl)amino]-1-phenylethyl]-5-methyl-1,2-oxazole-3-carboxamide
-
-
N-[2-[(4-methoxy-2,5-dimethylbenzyl)amino]-1-(2-methoxyphenyl)ethyl]-5-methyl-1,2-oxazole-3-carboxamide
-
-
N-[2-[(4-methoxy-2,5-dimethylbenzyl)amino]-1-(3-methoxyphenyl)ethyl]-5-methyl-1,2-oxazole-3-carboxamide
-
-
N-[2-[(4-methoxy-2,5-dimethylbenzyl)amino]-1-(4-methoxyphenyl)ethyl]-5-methyl-1,2-oxazole-3-carboxamide
-
-
N-[2-[(4-methoxy-2,5-dimethylbenzyl)amino]-1-phenylethyl]-1,2-oxazole-3-carboxamide
-
-
N-[2-[(4-methoxy-2,5-dimethylbenzyl)amino]-1-phenylethyl]-3-methyl-1,2-oxazole-5-carboxamide
-
-
N-[2-[(4-methoxy-2,5-dimethylbenzyl)amino]-1-phenylethyl]-5-methyl-1,2-oxazole-3-carboxamide
-
-
N-[2-[(4-methoxy-2,5-dimethylbenzyl)amino]-1-[4-(pyridin-4-yl)phenyl]ethyl]-5-methyl-1,2-oxazole-3-carboxamide
-
-
N-[2-[(4-methoxybenzyl)amino]-1-phenylethyl]-5-methyl-1,2-oxazole-3-carboxamide
-
-
p-chloromercuribenzoate
-
complete inhibition
phosphopyridoxyl sphinganine 1-phosphate
phosphopyridoxyl sphingosine 1-phosphate
Semicarbazide
sphinganine 1-phosphonate
-
competitive inhibitor
sphinganine phosphate
-
2D,3L-isomer is a competitive inhibitor, but 2L,3L-isomer does not influence the enzyme
Subtilisin
-
-
-
Thermolysin
-
-
-
threo-dihydro-sphingosine 1-phosphate
Trypsin
-
-
-
[(4-benzyl-phthalazin-1-yl)-2-methylpiperazin-1-yl]-nicotinonitrile
[(4-benzylphthalazin-1-yl)-2-methylpiperazin-1-yl]nicotinonitrile
-
[2-amino-2[2-(4-octylphenyl)ethyl]-3-hydroxypropyl]dihydrogen phosphate
additional information
-